Economopoulou, Panagiota
-
Vol 11, No 12 (December 31, 2019): Journal of Thoracic Disease - Original Article
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort
Abstract PDF Full Text